Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...
Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...
Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...
On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback